Clinical Trials Browser

Phase 1 × OTHER × IDH1 Mutation Myeloid Neoplasms × Clear all

NCT03564821 2025-11-04

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Phase 1 Completed

IDH1 Mutation Myeloid Neoplasms